- Active not recruitingPHASE1, PHASE2
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
This study is looking at new drug combinations for advanced cancers like ovarian, breast, lung, and stomach cancer. It checks how safe and effective they are, and how they work in the body.
For: Ovarian · Breast · SCLCUnited States · France · Israel - Active not recruitingPHASE1
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
This study is for people with bladder cancer that's spread and hasn't responded to previous treatment. It tests several new drug treatments, alone or in combination, to see if they're safe and effective. Doctors will check your tumour for specific changes to decide which treatment might be best for you.
For: Muscle Invasive Bladder CancerUnited States · Canada · France - Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance - Active not recruitingPHASE3
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
This study is looking at a new drug called MEDI4736 for people who have had surgery for a certain type of lung cancer. Researchers want to see if this new drug works better than no further treatment to help stop the cancer from coming back.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil